• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Predictors of Immune Checkpoint Inhibitor Response in ER+/HER2- Breast Cancer: A New Role for ESR1?

作者信息

Arima Jun, Chida Kohei, Wu Rongrong, Taniguchi Kohei, McKenery Amber, Morreale Brian G, Monell Andrea M, Abrams Scott I, Ebos John M L, Hakamada Kenichi, Ishikawa Takashi, Hagihara Seita, Kawaguchi Nao, Kuramoto Toru, Shima Takafumi, Hamamoto Hiroki, Tanaka Ryo, Imai Yoshiro, Kimura Kosei, Iwamoto Mitsuhiko, Lee Sang-Woong, Takabe Kazuaki

机构信息

Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Osaka, Japan.

出版信息

Ann Surg Oncol. 2025 Sep 17. doi: 10.1245/s10434-025-18377-4.

DOI:10.1245/s10434-025-18377-4
PMID:40960662
Abstract
摘要

相似文献

1
ASO Author Reflections: Predictors of Immune Checkpoint Inhibitor Response in ER+/HER2- Breast Cancer: A New Role for ESR1?ASO作者反思：雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌中免疫检查点抑制剂反应的预测因素：ESR1的新作用？
Ann Surg Oncol. 2025 Sep 17. doi: 10.1245/s10434-025-18377-4.
2
ESR1 Expression Negatively Correlates with Immune Cell Infiltration and Response to Immune Checkpoint Inhibitors in Estrogen Receptor-Positive/HER2-Negative Breast Cancer.ESR1表达与雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌中的免疫细胞浸润及免疫检查点抑制剂反应呈负相关。
Ann Surg Oncol. 2025 Sep 16. doi: 10.1245/s10434-025-18260-2.
3
First-Line Camizestrant for Emerging -Mutated Advanced Breast Cancer.针对新出现的特定突变晚期乳腺癌的一线用药卡米司他。
N Engl J Med. 2025 Jun 1. doi: 10.1056/NEJMoa2502929.
4
Assessment of , , , and mRNA in Hormone Receptor-Positive Early Breast Cancer: A Cross-Sectional Study.激素受体阳性早期乳腺癌中、、、和mRNA的评估：一项横断面研究
Health Sci Rep. 2025 Jul 15;8(7):e71062. doi: 10.1002/hsr2.71062. eCollection 2025 Jul.
5
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.拉索昔芬作为一种潜在的治疗芳香化酶抑制剂耐药性 ER 阳性乳腺癌的药物。
Breast Cancer Res. 2024 Jun 7;26(1):95. doi: 10.1186/s13058-024-01843-4.
6
Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.帕拉泽司琼，一种新型口服完全雌激素受体拮抗剂（CERAN）和选择性雌激素受体降解剂（SERD），用于雌激素受体阳性/人表皮生长因子受体2阴性晚期或转移性乳腺癌患者：1/2期研究结果。
Breast Cancer Res. 2025 Jul 1;27(1):119. doi: 10.1186/s13058-025-02049-y.
7
Tumor Immune Response as a Biomarker for Metastasis-Free Survival of Breast Cancer and Immune Checkpoint Inhibition Therapy: A Retrospective Cohort Study.肿瘤免疫反应作为乳腺癌无转移生存期和免疫检查点抑制治疗的生物标志物：一项回顾性队列研究
Breast Cancer (Auckl). 2025 Aug 24;19:11782234251363665. doi: 10.1177/11782234251363665. eCollection 2025.
8
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.用于治疗雌激素受体阳性晚期乳腺癌的蛋白酶靶向嵌合体（PROTAC）雌激素受体降解剂
Target Oncol. 2025 May;20(3):431-444. doi: 10.1007/s11523-025-01137-5. Epub 2025 May 6.
9
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.释放免疫检查点抑制剂在激素受体阳性/人表皮生长因子受体2阴性乳腺癌中的潜力：一项系统综述。
Cancers (Basel). 2025 Sep 8;17(17):2940. doi: 10.3390/cancers17172940.
10
Harmonization trial on testing strategies in ER+/HER2- breast cancer patients: an Italian experience.雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌患者检测策略的协调试验：意大利的经验
J Liq Biopsy. 2025 Jul 28;9:100314. doi: 10.1016/j.jlb.2025.100314. eCollection 2025 Sep.

本文引用的文献

1
ESR1 Expression Negatively Correlates with Immune Cell Infiltration and Response to Immune Checkpoint Inhibitors in Estrogen Receptor-Positive/HER2-Negative Breast Cancer.ESR1表达与雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌中的免疫细胞浸润及免疫检查点抑制剂反应呈负相关。
Ann Surg Oncol. 2025 Sep 16. doi: 10.1245/s10434-025-18260-2.
2
Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer.可切除胰腺癌患者新辅助放化疗与化疗的比较
Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-17988-1.
3
Gene Expression in Breast Cancer Is Associated With Worse Prognosis, but Better Response to Chemotherapy and Immunotherapy.
乳腺癌中的基因表达与较差的预后相关，但对化疗和免疫治疗的反应较好。
World J Oncol. 2025 Feb;16(1):120-130. doi: 10.14740/wjon1993. Epub 2025 Jan 13.
4
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.雌激素受体阳性、人表皮生长因子2阴性乳腺癌的新辅助化疗与免疫治疗
J Clin Oncol. 2024 Aug 1;42(22):2632-2636. doi: 10.1200/JCO.23.02614. Epub 2024 Apr 9.
5
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.术前化疗前后激素受体阳性乳腺癌的免疫微环境
Clin Cancer Res. 2019 Aug 1;25(15):4644-4655. doi: 10.1158/1078-0432.CCR-19-0173. Epub 2019 May 6.